Mediclinic International: a top FTSE 100 healthcare stock?

Mediclinic International plc (LON: MDC) shares are up 5% today. Are they worth a closer look?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When we talk about FTSE 100 healthcare stocks, names such as GlaxoSmithKline and AstraZeneca generally come to mind. However, there are several other healthcare stocks in the FTSE 100 index that may be worth considering for your portfolio.

One such stock is Mediclinic International (LSE: MDC). The £4.6bn market cap healthcare provider has released a full-year trading update today and its shares have jumped 5%. Let’s take a closer look at the company to see if the shares are worth buying.

Business description

Mediclinic is an international private healthcare group with operations in South Africa, Namibia, Switzerland and the United Arab Emirates. It also holds a 30% interest in UK specialist Spire Healthcare Group. The group is focused on providing acute care, specialist-oriented, multidisciplinary healthcare services.

It has experienced a challenging couple of years as lower patient volumes and expansion costs have weighed on profits. Investors have also been concerned with the group’s large debt pile. As a result, the shares have declined from over 1,100p back in August 2016 to just 655p today.

Yet today’s trading update sounded positive. The company appears to be moving in the right direction. Could a turnaround be on the cards?

Today’s update

Mediclinic advised this morning that the group expects to deliver adjusted financial results for the year that are “marginally ahead” of expectations, with a “significant second-half improvement” from the Middle East division. FY2018 revenue is expected to rise 2% in constant currency terms, while adjusted earnings are anticipated to be broadly flat on the prior year.

The group stated that its Middle East division is now entering an “expansionary phase” that is expected to drive a strong increase in revenue and improvements in margins over time. Furthermore, the Southern Africa division delivered second-half revenue growth ahead of expectations while in Switzerland, the Hirslanden division performed in line with expectations. Both of these divisions benefitted from cost-saving programmes and productivity initiatives implemented during the year.

CEO Danie Meintjes was upbeat in his outlook for the company, stating that the demand for healthcare continues to increase and that Mediclinic is well positioned to benefit and create long-term shareholder value.

Worth buying?

The long-term story here does sound appealing. And it appears that the company is now heading in the right direction after a challenging few years.

However, I’m not 100% convinced that the shares offer much value right now. The group expects earnings for the year to be approximately 30p per share. At the current share price, that places the stock on a relatively high trailing P/E of 21.8. For FY2019, analysts expect EPS of 32.4, which results in a forward-looking P/E of 20.2. The trailing dividend yield on the stock is low, at around 1.3%. Comparing these figures to those of other healthcare stocks in the FTSE 100, I think there are better stocks to buy at present. I’d pick up Glaxo or Smith & Nephew before Mediclinic International.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »